Where does Apotex Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Apotex Inc. ranks #8,327 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Apotex Inc. hold?

Apotex Inc. holds 38 US utility patents granted between 2016 and 2024, spanning 12 technology areas.

What is Apotex Inc.'s Innovation Score?

Apotex Inc. has an Innovation Score of 37.6 out of 100 (top 43% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Apotex Inc. focus on?

Apotex Inc.'s top technology area is C07D (Heterocyclic Compounds) with 29 patents, ranking #285 of 3,165 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Apotex Inc.'s patent grant rate increasing or decreasing?

Apotex Inc.'s recent grant velocity is +24% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Apotex Inc.'s patents?

Apotex Inc.'s patents average 15.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Apotex Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Apotex Inc.

USPTO PatentsView assignee record - 38 granted patents across 12 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Apotex ranks #8,327 of 49,997 tracked US assignees by granted-patent volume, with 38 patents across 12 technology areas.

#8,327
of 49,997 US assignees by volume: Top 43%
by Innovation Score (37.6/100): 15.0
avg claims per patent: +24%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8327 · Foreign Corporation #8,327 · 38 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 38 grants
UPPER-Q #8,327/49,997
PHOTO-FINISH All Purpose Networks
CPC-FOCUS C07D · 12 areas
INNOV-THIN 37.6/100
CLAIMS-RICH 15.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +24% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: All Purpose Networks, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Apotex’s 37.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.7 pts (34%) Velocity 3.7 pts (10%) Breadth 12.2 pts (32%) Claim depth 9.0 pts (24%)

Qualcomm Incorporated · highest

85
Apotex · this assignee

38
Bedoukian Research · near

38
Mplus · near

38
Quest Software · near

38
THE Mclean Hospital · near

38
3D Lighting… · lowest

7

What this shows Apotex's Innovation Score is 37.6/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Apotex?

Each dot is one of Apotex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Apotex’s own 15.0 claims/patent is at or below the 18.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Apotex vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Apotex's grants concentrate

Apotex Inc. is a focused PatentsView assignee: 12 CPC subclasses with 76.3% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2020 (9 grants) versus a trough of 1 in 2024. By volume, Apotex sits between ATT Southern Inc. and Bio-medical Engineering (HK) Limited.

Apotex's three-year grant acceleration

Apotex Inc. shows 10 grants in 2022–2024 against only 18 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

ATT Southern

38
Auctane

38
All Purpose Netwo…

38
Anest Iwata

38
Aqua-leisure Indu…

38
Aurea Software

38
Banner Life Scien…

38
Bio-medical Engin…

38
Apotex ◀

38

What this shows Apotex holds 38 patents at rank #8,330, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Apotex

By rank, the assignees closest to #8,330 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Apotex's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Apotex, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Apotex ranks #285 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Mplus Corp. 38 THE Mclean Hospital Corporation 38 Bedoukian Research, Inc. 38 Quest Software Inc. 38

Apotex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Apotex Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	3	7.9%
2017	2	5.3%
2018	5	13.2%
2019	7	18.4%
2020	9	23.7%
2021	2	5.3%
2022	5	13.2%
2023	4	10.5%
2024	1	2.6%

Which technologies does Apotex Inc. patent most?

C07D - Heterocyclic Compounds 29

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 24

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 15

C07C - Acyclic OR Carbocyclic Compounds 11

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C07K - Peptides 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Apotex Inc.'s patent record in context - here's where to go next.

Apotex Inc.'s lead technology class is C07D (Heterocyclic Compounds), 76.3% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #8,327 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Apotex Inc. against ATT Southern Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.